ProShares Ultra NASDAQ Biotechnology
31 hedge funds and large institutions have $21M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 5 closing their positions.
29% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $16.4M
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 30 → 31 (+1)
19% less capital invested
Capital invested by funds: $26M → $21M (-$5.02M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIA
RPG Investment Advisory
Pleasanton,
California
|
+$1.94M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.07M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$734K |
| 4 |
CT
CMT Trading
Chicago,
Illinois
|
+$634K |
| 5 |
HF
HRT Financial
New York
|
+$418K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
-$2.63M |
| 2 |
VF
Virtu Financial
New York
|
-$2.23M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.44M |
| 4 |
LPL Financial
San Diego,
California
|
-$819K |
| 5 |
Jane Street
New York
|
-$526K |
BIB Hedge Fund Activity: Q2 2016 in Review
31 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2016, worth a combined $21M — down 19% from $26M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BIB positions and 5 closed out — a net gain of 1 holder — while 7 added to existing stakes and 14 trimmed.
The largest buyer was RPG Investment Advisory, adding an estimated $1.94M. The largest seller was Opus Point Partners Management, exiting entirely with an estimated $2.63M sold.
- 31 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2016, up from 30 in Q1 2016.
- Funds reported $21M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2016, down 19% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2016 and 5 closed out, a net change of +1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2016 was RPG Investment Advisory, an estimated $1.94M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2016 was Opus Point Partners Management, an estimated $2.63M sold.
Based on aggregated 13F filings for Q2 2016.